Comment on ‘Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi‐Centre, Prospective, Observational Study (REVISE Study)’ (Endocrinology, Diabetes & Metabolism, 2026)